Haven Private LLC acquired a new stake in shares of Novartis AG (NYSE:NVS - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 2,939 shares of the company's stock, valued at approximately $286,000.
Other institutional investors also recently bought and sold shares of the company. Foundations Investment Advisors LLC boosted its holdings in shares of Novartis by 26.9% in the fourth quarter. Foundations Investment Advisors LLC now owns 89,074 shares of the company's stock worth $8,668,000 after buying an additional 18,894 shares during the last quarter. CWA Asset Management Group LLC lifted its position in Novartis by 20.1% during the fourth quarter. CWA Asset Management Group LLC now owns 30,840 shares of the company's stock valued at $3,001,000 after purchasing an additional 5,164 shares in the last quarter. Quantbot Technologies LP grew its holdings in Novartis by 135.5% during the third quarter. Quantbot Technologies LP now owns 39,976 shares of the company's stock valued at $4,598,000 after purchasing an additional 22,998 shares during the period. Chicago Partners Investment Group LLC purchased a new stake in Novartis in the fourth quarter worth about $239,000. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of Novartis by 13.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 157,256 shares of the company's stock worth $18,088,000 after buying an additional 18,990 shares during the period. Institutional investors own 13.12% of the company's stock.
Analysts Set New Price Targets
A number of research firms have commented on NVS. Barclays restated an "underweight" rating on shares of Novartis in a research note on Monday, February 3rd. HSBC downgraded shares of Novartis from a "hold" rating to a "reduce" rating in a research report on Wednesday, December 4th. Morgan Stanley assumed coverage on shares of Novartis in a report on Wednesday, February 12th. They issued an "underweight" rating for the company. StockNews.com raised Novartis from a "buy" rating to a "strong-buy" rating in a report on Saturday, February 8th. Finally, Erste Group Bank reiterated a "hold" rating on shares of Novartis in a research report on Tuesday, November 19th. Three research analysts have rated the stock with a sell rating, six have issued a hold rating, one has given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $123.38.
View Our Latest Analysis on NVS
Novartis Price Performance
Shares of NVS stock traded down $3.99 during trading hours on Tuesday, hitting $111.48. The stock had a trading volume of 2,021,182 shares, compared to its average volume of 2,066,343. The stock's 50-day moving average price is $104.38 and its two-hundred day moving average price is $107.87. Novartis AG has a one year low of $92.35 and a one year high of $120.92. The stock has a market capitalization of $227.87 billion, a price-to-earnings ratio of 18.96, a PEG ratio of 1.70 and a beta of 0.53. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.04 and a quick ratio of 0.84.
Novartis (NYSE:NVS - Get Free Report) last issued its quarterly earnings data on Friday, January 31st. The company reported $1.98 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.80 by $0.18. Novartis had a return on equity of 37.24% and a net margin of 23.56%. Equities analysts forecast that Novartis AG will post 8.45 EPS for the current year.
Novartis Profile
(
Free Report)
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.
Read More
Before you consider Novartis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novartis wasn't on the list.
While Novartis currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
